ScripScan:Suven Life Sciences Ltd
code:530239
Cmp:17
Story:Partnership business model with Innovator Drug Companies.Partnering development of under patent molecules.Partnering drug discovery and development of New Chemical Entities with global drug majors.Partnering with multinationals for contract manufacturing.Leveraging relationships with 25 global life science companies.Offering a clear value proposition to multinationals in cutting costs,time to market and outsourcing research capabilities.Successful transformation in supplying products from grams to tons.The company was very much in the limelight recently. The stock has recovered from its recent low of 15rs. The spike up in the stock was after the company announced that its has received four product patent approvals - three from Australia and one from New Zealand, which could be used for treating various central nervous disorders.These patents are valid through 2027. With these new patents, the company now has eleven patents from Australia and twelve from New Zealand. Financially, the company did not do well in Q1FY12. Though the company showed a rise in net income for the quarter at Rs.44.63 crore v/s Rs.35.92 crore in Q1FY11, its net profit showed a decline of 2.32% at Rs.3.36 crore. On an equity of Rs.11.67 crore, this Re.1 face value stock has an annualized EPS of Rs.1.16 and this discounts the current price by 15 times.One shouldnt expect huge returns till the company reports robust numbers.At present its a hold.
Subscribe to:
Post Comments (Atom)
Important Disclaimer&Privacy policy
This blog does not share personal information with third parties nor do we store any information about your visit to this blog other than to analyze and optimize your content and reading experience through the use of cookies.You can turn off the use of cookies at anytime by changing your specific browser settings.This privacy policy is subject to change without notice and was last updated on 20.3.2013. If you have any questions, feel free to contact me directly here: arunsharemarket@gmail.com
Investment in equity shares has its own risks.Sincere efforts have been made to present the right investment perspective.The information contained herein is based on analysis and up on sources that I consider reliable. I,however,do not vouch for the accuracy or the completeness thereof.This material is for personal information and am not responsible for any loss incurred based upon it & take no responsibility whatsoever for any financial profits or loss which may arise from the recommendations above.The stock price projections shown are not necessarily indicative of future price performance.The information herein, together with all estimates and forecasts, can change without notice.
No comments:
Post a Comment